Diabetes

Pharmacists leverage CGM and automated insulin delivery to personalize diabetes care, prevent errors, and expand equitable access to technology.

A drug already used to protect the kidneys may now offer a broader shield.

Diabetes technology shifts to continuous glucose monitoring, automated insulin delivery, and connected pens, empowering pharmacists to guide safer care.

The ACTIV-6 trial suggests early metformin may halve clinician-diagnosed long COVID risk, offering a low-cost option pharmacists can apply safely.

This decision marks a milestone in clinical pharmacy as it targets the underlying autoimmune destruction of pancreatic beta cells.

FDA clears first OTC CGM for children 2 years and older, expanding tracking beyond prescriptions for pediatric populations.

Pharmacists close these gaps through screening and prevention for patients.

Once-weekly mazdutide drives approximately 17% weight loss in Chinese adults with obesity, offering a dual GLP-1/glucagon metabolic option.

Medicare’s $35 insulin cap cuts cost swings, boosts adherence for high-burden patients, and highlights pharmacists’ role in preventing rationing.

New 9-year data shows some high-risk prediabetes patients progress to type 2 diabetes despite 8% weight loss.

In an evolving health care landscape bringing all providers into a primary care team, diabetes is no different and the pharmacist community can offer so much for patients.

Episode 11 addresses recent changes to the AACE diabetes guidelines and what pharmacists need to do to stay informed.

In part 2 of our interview with Sandra Leal, PharmD, MPH, she explored the ADA Standards of Care and how pharmacists are positioned to assist in interoperable diabetes management.

Older adults with type 2 diabetes often juggle 5 or more different prescriptions.

This regulatory milestone establishes inhaled insulin as the first and only noninjectable mealtime insulin option for children and adolescents.

Real-world data show GLP-1 drugs in type 1 diabetes cut heart and kidney risks, support weight loss, and appear safe with insulin adjustments.

As diabetes rises to be one of the most prominent chronic diseases globally, pharmacists have reached out as key resources for preventing and managing its complications.

Meta-analysis shows empagliflozin is superior to sitagliptin with metformin for glycemic control.

The FDA seeks to bar bulk compounding of semaglutide, tirzepatide, and liraglutide, spotlighting risks in online glucagon-like peptide-1 copies.

In part 2, Staci-Marie Norman, PharmD, CDCES, FAPhA, and Susan Cornell, PharmD, CDCES, FAPhA, FADCES, discuss the pharmacist’s ability to meander a booming medication class in GLP-1s.

New research shows inflammation and diabetes raise preterm birth risk, suggesting C-reactive protein testing.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.

Exploring clinical prioritization and macroeconomic investment, researchers examine the link between disease and economic burden of diabetes.

GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.